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Abstract 
With the emergence of extensively drug-resistant tuberculosis there is a strong need for new 
anti-tubercular drugs that work through novel mechanisms of action. The meta-cleavage 
product hydrolase, HsaD, has been demonstrated in a genome-wide screen to be critical to the 
survival of Mycobacterium tuberculosis in macrophages and is encoded in an operon 
involved in cholesterol catabolism, which is identical in M. tuberculosis and M. bovis BCG.   
In this work we demonstrate that a strain of M. bovis BCG with a deletion of hsaD was 
unable to grow on cholesterol as a sole carbon source. Using a fragment based approach, over 
1,000 compounds were screened by a combination of differential scanning fluorimetry, NMR 
spectroscopy and enzymatic assay with pure recombinant HsaD to identify potential 
inhibitors. Of seven chemically distinct “hits’’, two chemical classes of fragments were 
pursued further using commercially available analogue sub-libraries. Following 
determination of inhibitory potency, the binding of inhibitors in the vicinity of the active site 
of HsaD was confirmed by determining the X-ray crystallographic structure of HsaD with 
individual fragments bound. The compounds were also tested for inhibition of growth of M. 
tuberculosis on cholesterol. The most potent inhibitor of HsaD was found also to be the best 
inhibitor of mycobacterial growth on cholesterol-supplemented minimal medium. We 
propose that HsaD is a novel therapeutic target which should be fully exploited in order to 
design and discover new anti-tubercular drugs.  
 
Abbreviations: 4,9-DHSA, 4,5-9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10), 2-diene-
4-oic acid; ADC, albumin-dextrose-catalase; BCG, Bacillus Calmette–Guérin; CHES, N-
Cyclohexyl-2-aminoethanesulfonic acid; DSF, differential scanning fluorimetry; FBDD, 
fragment based drug discovery; FCS, fetal calf serum; HOPDA, 2-hydroxy-6-oxo-6-
phenylhexa-2,4-dienoic acid; LB, Luria-Bertani; MB, Middlebrook; MCP, meta-cleavage 
product; MDR-TB, multidrug-resistant tuberculosis; MIC, minimum inhibitory 
concentration; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NAT, 
arylamine N-acetyltransferase; OADC, oleic acid-albumin-dextrose-catalase; PMSF, 
phenylmethylsulfonyl fluoride; SAR, structure activity relationship; SPOTi, spot culture 
growth inhibition assay; STD, saturation transfer difference; TB, tuberculosis; TSP, 
(Trimethylsilyl)-propionic acid; WHO, World Health Organization; XDR-TB, extensively 
drug-resistant TB.  
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Introduction   
Tuberculosis (TB) remains a global health emergency with an estimated 9 million new cases 
and 1.5 million deaths every year (WHO, 2015). Importantly, 3.7% of new cases and 20% of 
previously treated patients are infected with multidrug-resistant tuberculosis (MDR-TB). 
Moreover, up to 9% of these MDR-TB cases are resistant to nearly all known treatments and 
considered as extensively drug resistant TB (XDR-TB). Current treatment modalities for 
drug-sensitive TB cases require continuous dosing for at least six months of chemotherapy 
leading to poor patient compliance, which further increases the rate of drug resistance (WHO, 
2015). There is a clear need for new anti-tubercular drugs, particularly those that shorten the 
treatment period. However the long-term and indefinite intracellular survival of 
Mycobacterium tuberculosis at different physiological states has made the development of 
novel therapeutics extremely challenging.  
Cholesterol has been identified as important  in the infection process of M. tuberculosis 
(Crowe et al., 2015; Kendall et al.,2007,2010, Lloyd-Evans et al., 2009; Lovewell et al., 
2016; Ouellet et al., 2011; Peyron et al., 2000) and is used as a carbon source during survival 
within macrophages ( Pandey et al., 2008; Rohde et al., 2012). In previous work we have 
demonstrated that an operon consisting of hsaA (Rv3567), hsaB (Rv3570), hsaC (Rv3568), 
hsaD (Rv3569) (Van der Geize et al., 2007) is involved in cholesterol metabolism. This 
operon was first identified in M. tuberculosis and also includes the gene encoding arylamine 
N-acetyltransferase (nat, Rv3566) (Anderton et al., 2006; Payton et al.; 2001) and then 
further characterized in other mycobacterial species (Evangelopoulos et al., 2014). It is 
currently believed that the NAT protein may metabolise the alkyl chain generated by 
cholesterol catabolism (Lack et al., 2009), whilst the other proteins are involved in the 
degradation of the sterol nucleus of cholesterol (Van der Geize et al., 2007;Griffin et 
al.,2011; 2012). Studies using transposon mutagenesis have shown that HsaC and HsaD are 
required for the survival of M. tuberculosis within macrophages (Rengarajan et al., 2005). 
The expression of hsaC gene was later demonstrated to be essential both in vitro and in vivo 
for infection of M. tuberculosis in guinea pigs (Yam et al., 2009). More recent studies have 
also implicated a role for the operon and HsaD in mycobacterial growth linked to cholesterol 
catabolism (Griffin et al., 2011). HsaD has also been shown to be overexpressed in 
hypervirulent strains of Mycobacterium bovis BCG during mouse infection (Blanco et al 
2009) and compounds with antitubercular activity have been identified as potential HsaD 
inhibitors via virtual screening (Rebollo-Lopez et al., 2015). 
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HsaD belongs to the superfamily of αβ-hydrolases that consists of the meta-cleavage product 
(MCP) hydrolase subfamily (Lack et al., 2008). HsaD catalyses the hydrolytic cleavage of the 
carbon-carbon bond, through a serine protease-like catalytic triad (Lack et al., 2008; Lack et 
al., 2010), of the MCP 4,5-9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oic 
acid (4,9-DHSA) in the cholesterol metabolism pathway (Van der Geize et al., 2007). In a 
previous study, we demonstrated that mechanism-based serine protease inhibitors can inhibit 
HsaD (Ryan et al., 2014) suggesting that an acyl enzyme intermediate may be formed during 
the reaction process in line with studies on the mechanism of other C-C bond hydrolases 
(Ruzzini et al., 2012;2013). As the HsaC protein (Yam et al., 2009) is unstable in oxygen, 
HsaD is a promising pharmacological target essential for M. tuberculosis infection. It is 
highly soluble as a stable recombinant protein (Lack et al., 2009) and there are multiple 
crystal structures available (Lack et al., 2008; Lack et al., 2010). Moreover HsaD has a very 
large active site cavity that makes it a good target for fragment based drug discovery (FBDD) 
(Silvestre et al., 2013). FBDD combines NMR, differential scanning fluorimetry (DSF) and 
crystallography to use weakly binding small molecules (<300Da) as building blocks to 
develop potent small molecular inhibitors. This approach has shown tremendous success in 
modern drug discovery (Hudson et al., 2012; Hung et al., 2016). 
In this study we investigate HsaD as a novel pharmacological target for tuberculosis  through  
generation of a specific gene deletion mutant  and describe the identification of compounds as 
inhibitors of HsaD  by a FBDD approach.  
 
Materials and methods 
All reagents were purchased from Sigma Aldrich (Poole, UK) unless otherwise stated. 3,5-
dichlorobenzenesulphonamide, 3-chloro-4-hydroxybenzoate and 4-toluenesulphonamide 
were obtained from TCI Europe. 3,5-diflurobenzenesulphonamide, 3,5-dichlorobenzamide 
and 3-bromobenzenesulphonamide were obtained from Apollo Scientific and ethyl-3,5–
dichloro-4-hydroxybenzoate was obtained from Maybridge. The fragment library used in this 
study was composed of 1258 compounds from commercial libraries supplied by Maybridge 
(Thermo Fisher Scientific: http://www.maybridge.com/), as previously described (Ciulli, 
Page 6 of 42
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
6 
 
2013; Van Molle et al., 2012). All library compounds were dissolved and stored in d6-
DMSO.  
 
All inhibitors were dissolved in DMSO. The DMSO final concentration in the assays was 5% 
(v/v) for the enzymatic assays and between 0.02% and 1.7% (v/v) for the growth 
experiments. The synthetic substrate, 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoic acid 
(HOPDA) was synthesised by Almac Sciences (Craigavon, Northern Ireland) as previously 
described and dissolved in ethanol (1% v/v) (Lack et al., 2009). The fragment library was 
prepared as previously described (Ciulli, 2013; Van Molle et al., 2012). 
Bacterial growth conditions 
M. tuberculosis, M. bovis BCG and Mycobacterium smegmatis mc2155 liquid cultures were 
grown in Middlebrook (MB) 7H9 broth containing 10% (v/v) ADC (albumin-dextrose-
catalase), 0.2% (v/v) glycerol and 0.05% (v/v) Tween-80. Mycobacterial strains were also 
grown on MB7H10 agar containing 10% (v/v) OADC (oleic acid-albumin-dextrose-catalase) 
and 0.5% (v/v) glycerol. M. tuberculosis cultures were grown in 10 mL broth in a 30 mL 
vials as standing cultures, M. bovis BCG in 100 mL broth in a roller bottle rolling cultures at 
2 rpm and M. smegmatis in 10 mL in a 50 mL centrifuge tubes rotating at 180 rpm all in a 
37°C incubator, unless specified otherwise. ∆hsaD M. bovis BCG was further supplemented 
with 50 µg/mL hygromycin.  
Growth curve comparison of the wild-type and ∆hsaD M. bovis BCG were done in minimal 
medium containing 0.05% (v/v) tyloxapol and 0.05% (v/v) ethanol with either a) no 
additional carbon source, b) 100 µg/mL glycerol or, c) 100 µg/mL cholesterol. An equivalent 
number of bacteria (6 x 108) were added to start the cultures and the bacterial growth rate was 
measured by monitoring the OD600 daily for 16 days.  
E. coli JM109 cells were grown in Luria-Bertani (LB) broth 10 mL of a centrifuge tube 
rotating at 180 rpm a 37°C incubator. LB agar was used for solid growth of E.coli strains at 
37°C, unless specified otherwise.  
 
Generation of the ∆hsaD gene deletion 
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Deletion of the hsaD gene was performed using specialised transduction as previously 
described (Bardarov et al., 2002). Briefly, the upstream and downstream flanking DNA 
regions of the hsaD gene were amplified by PCR using the following pair of oligonucleotide 
primers for the upstream flanking DNA region 5’-
TTTTTTTTGCATAAATTGCAGGCACCGTAGGCCAT-3’ and 5’-
TTTTTTTTGCATTTCTTGCAGTGACGTCCATTCAACA-3’ as the forward and reverse 
primers respectively with a BstAPI restriction site (underlined). The primers for the 
downstream flanking region were 5’-
TTTTTTTTCACAGAGTGCTTGACCGAGGCAATTGGAGAC-3’ and 5’-
TTTTTTTTCACCTTGTGCACCTGTTGGGCGGGC-3’ as the forward right and reverse 
primers respectively with a DraIII restriction site (underlined). The upstream and 
downstream products were subsequently digested with DraIII and BstAPI, respectively, and 
ligated with PfIMI-digested p0004s vector arms. The knockout construct was linearised 
following digestion with PacI and cloned into phAE159. Both pAES and phAE159 were 
subsequently digested with PacI, g l purified and ligated with T4 DNA ligase. The ligation 
mixture was then packaged into λ phag  heads by in vitro packaging, transduced into E. coli 
and plated on LB agar supplemented with hygromycin. Following validation the phasmids 
were then electroporated into M. smegmatis and grown at a permissive temperature (30°C) to 
generate mycobacteriophages. The resulting high-titre mycobacteriophages were then used to 
transduce the recipient mycobacteria at 37°C (non-permissive temperature). The correct 
identity of loss-of-function mutations was confirmed by PCR amplifications with primers 
against the internal hsaD gene (forward: 5’ AAGTCGGCTCCGGC 3’ reverse: 5’ 
TGGCCGTCGACCAGC 3’) and the region flanking the hsaD deletion (forward: 5’ 
GATGCTCATCTGCCACC 3’ reverse: 5’ ATGACAGCTACCGAGGAAT 3’). 
 
Intracellular survival of ∆hsaD M. bovis BCG in macrophages 
The RAW264.7 mouse macrophage cells were grown as a monolayer in RPMI-1640 media 
(GIBCO, Paisley, UK), supplemented with 1% (w/v) L-glutamine and 10% (v/v) foetal calf 
serum (FCS) at 37°C with 5% CO2. For the intracellular survival assays, RAW264.7 cells 
were plated approximately 24 hours prior to infection on 6-well plates in the presence of 2 
mL RPMI (supplemented with 10% FCS) as described (Bhakta et al., 2004;Westwood et al., 
2010). Cells were subsequently washed with fresh media, infected with M. bovis BCG at a 
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multiplicity of infection of 20 (i.e for every 1 RAW264.7 cell, 20 cells of M. bovis BCG were 
added) and incubated for 2 h. Cells were then washed twice with PBS and re-suspended in 
fresh media. The media was later removed and the cells were lysed with 1 mL of sterile 
distilled water for 10 min at 0, 24, 48, 72 and 120 h. The number of intracellular bacteria was 
determined by serially diluting the lysate, plating it on MB7H10 agar plates and incubating at 
37°C for 3-4 weeks.  
 
Effect of inhibitors against M. tuberculosis grown in cholesterol 
Growth on agar was carried out as follows: The minimum inhibitory concentrations (MIC) of 
selected inhibitors were determined using the spot culture growth inhibition assay (SPOTi) 
performed in 24-well plates with slight modifications (Evangelopoulos & Bhakta., 2010). 
Briefly, mycobacteria were plated on minimal agar based media containing: asparagine (0.5 
g/L), KH2PO4 (1.0 g/L), Na2HPO4 (2.5 g/L), ferric ammonium citrate (50 mg/L), 
MgSO4,7H2O (0.5 g/L), CaCl2 (0.5 mg/L), ZnSO4 (0.1 mg/L), agar (1.5% w/v) and either 
glycerol (0.1% v/v) or cholesterol (0.01% w/v). Fragments dissolved in DMSO (0.0125 
µg/mL, 0.025 µg/mL, 0.05 µg/mL, 0.1 µg/mL, and 0.2 µg/mL) or DMSO alone were mixed 
with 2 mL of the minimal media with cholesterol per well. The final DMSO concentration in 
the wells containing fragments was 0.2%. In addition a well with 0.2% DMSO only as well 
as isoniazid at various concentrations (0.001 µg/mL, 0.01 µg/mL, 0.1 µg/mL, 1 µg/mL and 
10 µg/mL) were used as positive controls. The plates were then inoculated with 2 µL 
(approximately 103 viable cells) of a mid-log phase culture of either M. bovis BCG or M. 
tuberculosis that was added in the centre of each well and allowed to soak before the plates 
were sealed with para-film, wrapped with aluminium foil and incubated at 37°C for 2 weeks 
until a spot of colonies were developed in the control wells. The MIC was determined as the 
lowest concentration in the well where mycobacterial growth was not evident.  
Effect of inhibitors against E. coli  
An overnight culture of E. coli JM109 cells grown as stated before was diluted in LB media 
to a final OD600 of 0.1 and acted as a working culture. 10µL of this working culture was used 
to inoculate a 96 well plate containing 90µL of LB media with a range of inhibitor 
concentrations up to 100 µg/mL. The maximum DMSO concentration in the well was 1.7% 
(v/v). The plates were then transferred into the Tecan M200 Infinite Pro spectrophotometer 
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where they grew at 37°C as standing cultures with absorbance measurements at 600nm  taken 
every hour for 4 hours 
Cytotoxicity against mammalian cells 
Cytotoxicity was tested using CCL-228 colorectal cancer cells (American Tissue Culture 
Collection Manassas, VA). Cells were cultured in Dulbecco’s Minimum Essential Medium 
(GIBCO, UK), supplemented with 10% (v/v) foetal bovine serum (FBS; Sigma-Aldrich, 
Poole, UK), 10,000U penicillin, 10 mg/mL streptomycin in 0.9% NaCl (Sigma-Aldrich), and 
maintained at 37°C in a humidified atmosphere with 5% CO2. Cells were seeded in 96-well 
plates (20,000 cells/well) and treated for 48 h after which they were incubated with 100µL of 
50µg/mL MTT solution in phenol red free DMEM (GIBCO) for 3 h in the dark at 37°C. The 
MTT was removed and the crystals solubilised with 100µL DMSO for 15 min at room 
temperature with gentle shaking. The intensity was measured colorimetrically at 570 nm 
using the M200 Infinite Pro plate reader (Tecan) and percent growth was calculated.  
Fragment based drug discovery 
Recombinant HsaD was prepared as described previously (Lack et al 2009). Differential 
scanning fluorimetry (DSF) was performed on a total of 1258 fragments as described 
previously (Niesen et al., 2007), using 0.4-1 µM HsaD in the presence of 2.5× SYPRO 
orange (Invitrogen) and 2.5 mM of compound (0.5 µL from a 0.1 M stock) at a final volume 
of 100 µL per well (final DMSO concentration of 2.5%) in 50 mM HEPES 300 mM NaCl pH 
7.5. Fluorescence was monitored using an Agilent Mx3005p qPCR instrument (Santa Clara, 
USA). The fluorescence excitation and emission wavelengths were 483 and 533 nm. The 
output data was plotted as derivative of the fluorescence versus temperature, and the 
maximum of such derivative over temperature was determined as the melting temperature 
(TM). Hits from the primary DSF screen were identified by the shift in TM compared to HsaD 
with vehicle (>2× st. dev. of control samples) and were further re-tested twice to confirm the 
results.  
NMR fragment screening 
Confirmed hits were validated by ligand-observed NMR spectroscopy (Ciulli & Abell,  2007;  
Ciulli, 2013; Dalvit et al., 2001; Ferguson et al., 2013). All NMR experiments were carried 
out at 278 K on a Bruker Avance 700 MHz equipped with a 5 mm triple TXI cryoprobe with 
z gradients. Relaxation‐edited NMR experiments incorporated a CPMG  spin-lock time of 
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200 ms before the acquisition period (Carr & Purcell,  1954). . Saturation Transfer Difference 
(STD) NMR experiments employed a 40 ms selective Gaussian 180° shaped pulse at a 
frequency alternating between ‘on resonance’ (0.5 ppm) and ‘off resonance’ (~80 ppm) after 
every scan (Mayer & Meyer, 1999). Water suppression was achieved by using a W5 
Watergate gradient spin-echo pulse sequence (Piotto et al., 1992). WaterLOGSY experiments 
(Dalvit et al., 2000;2001) employed a 20 ms selective Gaussian 180° shaped pulse at the 
water frequency and an NOE mixing time of 1 s. Water suppression was achieved using a 
double‐gradient echo excitation sculpting sequence with gradients. The resulting spectra were 
analyzed using Topspin 2.0 software (Bruker). All samples were made up to a total volume of 
200 µL in 3 mm capillaries, and contained 1.2 mM fragment, 50 mM Tris-HCl buffer at pH 
7.5, 10% v/v D2O, and 2.4% v/v DMSO-d6. (Trimethylsilyl)-propionic acid-d4 (TSP) was 
present at 20 µM concentration in all samples for calibration purposes. A protein only control 
sample was run as buffer control. Each fragment was run as 3 samples – (A-C). A) Fragment 
only; B) Fragment + protein (10 µM HsaD); C) Fragment +HsaD + displacer compound 
PMSF (100 µM).  
 
Enzymatic assays 
Following the initial identification of fragments from the fragment based drug design library, 
inhibition assays were carried out as previously described (Ryan et al., 2014) in the presence 
of 1 mM with compounds 1-7. Subsequently, compounds that were capable of inhibiting the 
cleavage of HOPDA by HsaD, were further selected for IC50 determination using a range of 
concentrations (1 mM, 0.5 mM, 0.375 mM, 0.25 mM, 0.125 mM, 0.05 mM and 0 mM or 3.5 
mM, 3 mM, 2.5 mM, 2 mM, 1.5 mM, 1 mM, 0.5 mM and 0 mM). Briefly pure HsaD (16 
µg/mL in 100 mM phosphate buffer pH 7.5, 20 mM NaCl) was added to the reaction mixture 
in the presence of 100 µM HOPDA (final concentration of 1% ethanol v/v) and inhibitor 
(final DMSO concentration of 5%) in a final volume of 100 µL. The enzymatic activity was 
measured by monitoring the absorbance at 450 nm at 21°C using a M200 Infinite Pro plate 
reader (Tecan) and the IC50 was determined using GraphPad Prism. The ε450 of HOPDA was 
measured as 13,200 M-1cm-1.  
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Solution of the structures of HsaD with Fragments 2, 27 and 32 
Crystals of apo-HsaD were grown as described previously (Lack et al., 2008). All fragments 
were dissolved directly into the cryoprotectant containing 30 % (w/v) PEG-3000, 0.1 M 
CHES pH 9.5, 25% (v/v) glycerol, at concentrations of between 15 mM and 50 mM. Crystals 
were transferred into the cryoprotectant containing one of the fragments and allowed to soak 
overnight at 21°C before flash freezing for analysis.  
Data collection for the structures of HsaD bound to 2, 27 and 32 were all performed at the 
Diamond Light source (Oxon, UK) using beamline I24 in the case of the structure with 2 and 
using beamline I03 for the others. In all cases initial processing was performed via Xia2 
(Winter, 2010) using XDS (Kabsch, 2010) to index and either Scala (2) (Evans, 2006) or 
Aimless (Collaborative Computational Project, 1994) (Winn et al., 2011) (27 and 32), to 
merge and scale the data. The structure was solved via molecular replacement using 
PHASER (McCoy et al., 2007) using the structure of apo-HsaD (PDB code, 2vf2) (Lack et 
al., 2008) stripped of all ligands as a search model. The atomic models were rebuilt in COOT 
(Emsley et al., 2010) and refined using REFMAC (Murshudov et al., 1997) and PHENIX 
(Adams et al., 2010). Model restraints for 2, 27 and 32 were generated in eLBOW (Moriarty 
et al., 2009).  
 
Results and Discussion 
Growth 
Deletion of hsaD in M. bovis BCG (∆hsaD) was generated using a mycobacteriophage-based 
knockout method (Bardarov et al., 2002). All of the hygromycin resistant colonies tested 
were the correct mutant. Our results are in accordance with previous studies, which have 
reported that approximately 95% of antibiotic-resistant transductants were the correct 
genotype (Bardarov et al., 2002).  
When grown in MB7H9 broth (Figure 1A) or in minimal medium (Figure 1B) the deletion of 
hsaD had no apparent effect on bacterial growth when compared with M. bovis BCG. 
However, when the minimal medium was supplemented with cholesterol (Figure 1C), a 
significant difference between the two strains was observed. Whilst the growth of the wild 
type strain was very similar to that in minimal medium alone, the growth of ∆hsaD M. bovis 
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BCG was significantly inhibited in the presence of cholesterol as compared to M. bovis BCG 
(Figures 1B & C). The growth of ∆hsaD M. bovis BCG in the presence of cholesterol was 
suppressed compared with growth in minimal medium alone. It has been observed that when 
the ∆hsaC M. tuberculosis H37Rv strain is grown in minimal medium with cholesterol there 
is a change in the appearance of liquid cultures such that they develop a pink colour (Yam et 
al., 2009). We observed the same effect when hsaD is deleted from M. smegmatis 
(Supplementary Figure 1) and grown on cholesterol as carbon source.  Therefore, similar to 
the “pink” metabolite of the ∆hsaC M. tuberculosis we propose that deletion of hsaD results 
in inhibition of growth of M. bovis BCG on cholesterol as a result of accumulation of an 
inhibitory metabolite. Growth in minimal medium on glycerol as the sole carbon source is 
supported in both the ∆hsaD strain and M bovis BCG. The gene deleted strain showed a 
slight lag in rate of growth although it caught up by day 16, reaching the same optical density 
(OD600 = 1.5) (Figure 1D). These data mirror previous findings on deletion of hsaD and other 
essential genes involved in cholesterol catabolism from M. tuberculosis (Griffin et al., 2011).  
Additionally it has been observed that hsaD expression is significantly increased in M. 
smegmatis when grown on cholesterol (Uhía et al., 2012) and genome wide studies with M. 
smegmatis grown on cholesterol have also pointed to an essential role  role for (Li et al., 
2016). 
Growth in minimal medium on glycerol as the sole carbon source is supported in both the 
∆hsaD strain and M bovis BCG. The gene deleted strain showed a slight lag in rate of growth 
although it caught up by day 16, reaching the same optical density (OD600 = 1.5) (Figure 1D). 
These data mirror previous findings on deletion of hsaD and other essential genes involved in 
cholesterol catabolism from M. tuberculosis (Griffin et al., 2011).   
Whole genome studies have previously identified the role of HsaD in the survival of M. 
tuberculosis within macrophages (Sassetti et al., 2003; Griffin et al., 2011). It has also been 
demonstrated that other genes in the operon (hsaC and nat) are essential for survival of M. 
bovis BCG in macrophage (Anderton et al., 2006; Bhakta et al., 2004). We therefore 
investigated the intracellular survival of the wildtype and ∆hsaD strains of M. bovis BCG 
within RAW246.7 mouse macrophages. Similar to ∆hsaC and ∆nat strains, there was a 
reduction in intracellular growth of the ∆hsaD strain as compared to the M. bovis BCG 
(Figure 1E). This is consistent with the whole genome studies and studies identifying the role 
of other members of this operon in the metabolism of cholesterol, which has been identified 
as controlled as the Kst-Regulon (Kendall et al., 2007;  Uhia et al., 2012)).  
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Identification of chemical fragments as inhibitors of HsaD 
The studies described above add to the growing weight of evidence that the operon in which 
hsaD is encoded along with the nat gene in the same gene cluster (Anderton et al., 2006) are 
essential for intracellular survival of mycobacteria and also that the gene product are required 
for cholesterol metabolism in M. bovis BCG and M. tuberculosis (Kendall et al., 2010; Van 
der Geize et al., 2007; Yam et al., 2009). Given this importance, we speculated that the hsaD 
gene is a potential target for anti-tubercular agents. Supporting drug design, the crystal 
structure of HsaD has been established to better than 2 Å resolution with the substrate 
HOPDA bound and shows that the active site cleft is over 30 Å3, which is a good prospect for 
a fragment based approach to identifying inhibitors (Lack et al., 2010). HsaD is also a stable 
soluble protein which crystallises readily (Ryan et al., 2014). Moreover, chemical inhibitors 
of HsaAB were found to dramatically decrease the intracellular proliferation of M. 
tuberculosis in macrophages (Vand rVen et al., 2015). 
A commercial library of rule-of-three compliant 1258 fragments (Silvestre et al.,2013) was 
screened by DSF. The melting temperature of pure recombinant HsaD was monitored in the 
presence of the fragments. The melting temperature of HsaD in previous studies (Lack et al., 
2009) had been determined by circular dichroism and loss of enzymatic activity of the protein 
itself to be between 69 and 72 oC. The high melting temperature was confirmed by DSF 
monitored by SYPRO Orange to be 72.7 (average mean value from quadruplicates across 17 
plates) +/- 0.21 oC (average SD from quadruplicates across 17 plates) in the presence of 
solvent and no added fragment. Fragments were identified as potential binders to purified 
HsaD when a shift was monitored in the melting temperature of greater than two standard 
deviations from the mean melting temperature of pure HsaD alone (Table 1). Hit compounds 
(18) from the primary screen were re-tested in duplicates in the thermal shift assay, from 
which 8 confirmed. The validated fragments were also tested as inhibitors of HsaD at a 
concentration of 1 mM of the compound (Figure 2) and were in addition tested by saturation 
transfer NMR for displacement by PMSF, an already identified inhibitor (Ryan et al., 2014) 
(Table 1 & Figure 2A).   
From this combination of methods, a series of seven distinct fragments were identified as 
binders. Fragment 1 was not pursued further due to its insolubility at 1 mM. In addition to the 
“hits” from the screen, a selection of 20 compounds from the library which showed no 
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evidence of binding by the DSF criteria, were also tested at 1 mM as inhibitors of HsaD and 
none were found to inhibit the enzyme (Data not shown) . From the initial inhibition studies 
at 1 mM, two compounds looked promising - compound 2 and compound 6, which produced 
38 % and 60% inhibition respectively (Figure 2). Fragment 2 is a sulphonamide and fragment 
6 is a hydroxybenzoate. 
When tested at a range of concentrations, compound 2 (3,5-dichlorobenzenesulfonamide) is 
an inhibitor of HsaD with an IC50 of 0.43 mM (Table 2) and fragment 6 (ethyl 3,5-dichloro-4-
hydroxybenzoate), despite it not being displaced by PMSF (Table 1) , is also an inhibitor of 
HsaD with an IC50 of 0.55 mM (Table 2). 
The fragments which were identified were distinct from previously identified substrates 
(Lack et al., 2010) and also distinct from putative inhibitors identified from a virtual screen 
(Rebollo-Lopez et al., 2015) but interestingly bear some resemblance to the central moiety of 
an inhibitor identified as targeting the HsaAB protein complex of the same operon 
(Vanderven et al, 2015).  
A small series of compounds related to each of the two classes of hit fragments 2 and 6 was 
tested for inhibition of HsaD (Supplementary table 1). 
Derivatives of fragment 2 as inhibitors of HsaD 
We investigated the small series of fragments modified around Compound 2 which has two 
chlorine atoms at the meta position. We investigated the effects of altering the position and 
number of chlorines in the molecule as well as substituting different halide groups. Removal 
of one chlorine from position 3 (Compound 9) was detrimental to the inhibitory potency and 
the IC50 was increased more than 10 fold to 5.14 mM (Supplementary table 1). Removal of 
both the chlorine atoms as in compound 8 (Supplementary Table 1 & Table 2), destroyed 
inhibition of HsaD completely. Substitution of the chlorines by fluorine (Fragment 10) also 
resulted in loss of inhibition of HsaD (Supplementary Table 1).Having a single chlorine in 
the para position (Fragment 13) did not possess any inhibitory effects on HsaD 
(Supplementary Table 1).  
Altering the position of chlorine from meta to the ortho position (Fragment 11) likewise 
resulted in a decreased inhibitory effect (IC50 1.96 mM) compared with fragment 2 and 
changing the chlorines to trifluoromethyl compounds (fragment 12) showed poorer inhibition 
as compared to the initial compound with less than 50% inhibition being reached. 
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(Supplementary Table 1). Mono-substituted benzenesulfonamides with a bromine in position 
3 (Fragment 14), like the mono-chlorinated fragment, produced a similar IC50 of 2.74 mM.  
The library of fragments used for these studies also incorporated sulphonamide fragments 
with the addition of nitro-, amino-, methyl-, methoxy-, hydroxy-, and carboxy- groups on 
various positions of the benzene ring. None of the modifications including these side groups 
were capable of inhibiting HsaD (Fragments 15-23) with the exception of Fragment 20 
which, with an IC50 of 92.6 mM,   was an extremely poor inhibitor.  
A derivative of Fragment 2, 3,5-dichlorosulfanilamide in which an amide group was 
incorporated in position 4 of the benzene ring, was able to inhibit HsaD with an IC50 of 0.184 
mM (Fragment 24) (Table 2 and Supplementary Table 1). Addition of a dimethyl group on 
the nitrogen (Fragment 25), however reduced the inhibitory effect on HsaD with an IC50 of 
3.63 mM. Replacement of the chlorines with bromines (Fragment 26) reduced the inhibitory 
potency compared with the parent compound to IC50 2.16 mM.  
The important features for inhibition of HsaD by derivatives of 2 appear to be  a para 
hydroxyl group on the aromatic  ring and two chlorines as meta substituents and the 
inhibitory potency (IC50 of 0.27mM) of fragment 27 supports this conclusion. Fragment 27 
also has a sulfonate group  at position 1 (Table 2). . 
 
Derivatives of compound 6 as inhibitors of HsaD 
A small group of hydroxybenzoate analogues were tested for comparison with compound 6 
as inhibitors of HsaD.  
Like compound 2, compound 6 has meta (3,5) substituted chlorine atoms and the position and 
number of chlorine substituents on the aromatic ring was altered as well as the presence of 
the 4-hydroxyl group. 
Ethyl 3,5-dichloro-4-hydroxybenzoate (Fragment 6) inhibited HsaD (IC50 0.55 mM). When 
the hydroxyl group was removed there was no inhibition of HsaD (Fragment 28) and when 
either one or both of the chlorine atoms were removed no inhibition was then observed. 
Fragment 29 with only one chlorine at the 3 position was not inhibitory and the same was 
true when both chlorines were missing (Compound 30).  
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An analogue in which both the chlorines are present and the 4 hydroxyl is present but there is 
a change in the ester substituent on the 1 position to a carboxylate group (3,5-dichloro-4-
hydroxybenzoic acid - Fragment 32) has the same IC50 value of 0.54 mM as the parent 
compound (Table 2B and Supplementary table 1). If the hydroxyl group in this charged 
compound is substituted by an amino group (fragment 33), the IC50 remains the same (0.54 
mM). Interestingly, altering the ethyl substituent on the carboxylate group to a methyl group 
(compound 31) was inhibitory but with a slightly higher IC50 (0.73 mM).  
To further elucidate the importance of the chlorines on positions 3 and 5, these were 
rearranged into positions 1 and 3 with the addition of a nitro group in position 6 (Fragment 
35). The resulting compound was less inhibitory, with an IC50 of 2.14 mM. Removal of the 
chlorines and only the presence of the carboxylic acid and amine group in positions 1 and 4 
of the benzene ring respectively (Fragment 36) and the amine in position 3 (Fragment 37), 
completely reversed the inhibitory effect (Supplementary Table 1). 
These studies supported the conclusion that the presence of chlorine substituents on the ring 
at the meta positions and the presence of a hydroxyl at the para position are important 
features for inhibition of HsaD.  
Structural studies of HsaD with inhibitors 
In order to identify the mode of binding of the inhibitors which were identified, structural 
studies were carried out using three different inhibitors : Compound 2 (IC50, 0.55mM) and an 
analogue (compound 27, IC50, 0.27mM) were chosen as representatives of the sulphonamide 
series and compound 32 (IC50, 0.54mM) was chosen as a representative of the 
hydroxybenzoate class. The latter compound was chosen in preference to the parent 
compound because it is more soluble. Crystals of HsaD were soaked with the inhibitory 
fragments.  
The structure of HsaD has been determined alone (Lack et al., 2008) to 2.6 Å and the 
structure of an inactive S114A mutant of HsaD   has been determined at resolutions of better 
than 2 Å with one of several different substrates bound (Lack et al., 2010). It was necessary 
to use the inactive version of HsaD in order for the substrate/protein complex to be stable 
enough for crystallisation. In each of the crystal structures, the asymmetric unit consists of 2 
protomers of identical polypeptide chains with one protomer being assigned as the A chain 
and the other as the B chain. These protomers are identical and each folds to form an α/β 
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hydrolase fold which contains an active site including  the catalytic triad (Ser114, His269 and 
Asp 241). (Lack et al., 2008; Lack et al., 2010).  
The crystal structure of HsaD with compound 2, was obtained to a resolution of 2.1 Å. The 
crystal structure with 3,5-dichloro-4-hydroxybenzenesulphonic acid (fragment 27) was 
obtained at a resolution of 2.68 Å and the structure of HsaD was also obtained where the 
ligand bound was a derivative of hydroxybenzoic acid ( 3,5-dichloro-4-hydroxybenzoic acid 
Fragment  32), at a resolution of 2.27 Å.  
The crystal structures of each of these ligand bound structures can be compared with the 
structure of HsaD alone (Figure 3A). With the exception of a 55° rotation of the side chain of 
Trp270, which is only observed in the structure of HsaD with compound 2, there are no major 
conformational changes compared with structure of apo-HsaD (overall RMSD 0.2 - Figure 
3). The binding of substrate molecules to HsaD revealed the presence of two different 
conformations, an open conformation for the apo-enzyme and a closed conformation when 
the substrate was bound. However, there was no change in the juxtaposition of the active site 
residues in the main catalytic pocket. The same is true on the binding of the inhibitors which 
have been investigated here (Figure 3A).  
Two molecules of fragmentss 2 and 27 were observed bound to HsaD, in their respective 
structures: one molecule was bound in each of the active sites of the protomers  in the dimer 
in the asymmetric unit. In each of these cases the orientation of the ligand was 
superimposable in its orientation in each of the two active sites in the dimer. 
Compound 32 was found in only one of the active sites of the dimer in the asymmetric unit, 
with the A chain active site being unoccupied. This reflects the data obtained with the 
substrate bound structures (Lack et al., 2010). The inhibitor binding sites each overlap with 
the binding site of the substrate from previous structures (Figure 4D) and are close to the 
active site Ser (Fig 3B-D). These structural studies confirm the specificity of the screening 
process in identifying inhibitors of HsaD.  
Binding of 2 and its analogue 27 to HsaD 
The structure of HsaD bound to fragment 2 allowed the unambiguous determination of the 
fragment’s binding orientation. Fragment 2 binds within the active site with its sulphonamide 
group making short-range hydrogen bonds with the side chain of Asn244 (Figure 3B). It also 
forms a hydrogen bond with the backbone amide of Gly140 and a water bridged interaction 
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with the side chain of Asn89. The benzene ring forms hydrophobic contacts with Gly46 and 
the side chains of Leu115, Leu158 and Val243. One chlorine forms contacts with the side 
chains of Met208 and Phe220, while the other contacts the side chains of Phe173 and His269.  
The number of hydrophobic contacts made by the chlorines explains why removal of one or 
both has a detrimental effect on fragment binding (Fragments 8 and 9) and also why 
replacement of the chlorines with polar functional groups is energetically unfavourable 
Fragments (16, 18, 20). The importance of the interactions of chlorines at positions 3 and 5 
also explains the inability of 17, 21 and 22 to inhibit HsaD. The hydrophobic contacts with 
Met208 and Phe220 are relatively long range (4.3 Å and 4.8 Å respectively) which indicates 
why the bromine of the inhibitory fragment 14 could be accommodated.  
The short-range hydrogen bond formed by the sulphonamide nitrogen explains the 
detrimental effect observed by double methylation of this group in fragment 25. 
Accommodation of the sulphanilamide of 24 in the current orientation would not be possible 
due to the distance between the fragment’s ring and Gly46 being too short to allow 
accommodation of an amine group in b tween (3.7 Å).  
Fragment 27 binds with its acidic group at the entrance of the polar sub-pocket (Fig 3C) that 
binds the dienoate moieties of HOPDA and 4,9-DHSA (Lack et al., 2010). The sulphonate 
group of 27 forms hydrogen bonds with the side chain of Trp270 as well as the backbone 
amides of Gly45 and Gly46 (Figure 3C). The sulphonate also forms a salt bridge interaction 
with the side chain of Arg192 (4.5 Å). One of the chlorines of 27 fits into a hydrophobic 
pocket formed by the side chains of Leu158, Phe173, Met177 and Val243 (all distances 
<4Å). The other chlorine interacts with Gly45 and the side chain of Leu115. 
The acidic compound 27, binds in a different orientation to the uncharged sulphonamide 2 
(Figure 4B). The charged sulphonate group of 27 may drive its binding to the polar pocket of 
the active site where it is able to form the salt bridge with Arg192 that could not be formed 
with the neutral sulphonamide of 2. This clear distinction in the binding modes of fragments 
that have charged versus simply polar groups provides useful information for modifying the 
fragments to improve affinity.  
Binding of fragment 32 to HsaD 
Fragment 32 binds in an almost coplanar conformation to 27 (Figure 3D). However, its 
binding position is shifted by around 1.8 Å outward from the polar sub-site (Figure 4A). As a 
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result, the carboxyl group of 32 is not inserted as far into the pocket as the sulphonate of 27. 
The carboxyl group forms hydrogen bonds with the side chain of Ser114 and the backbone 
amides of Gly45 and Gly46 (Figure 3D). This also means the fragment is unlikely to form a 
salt bridge with Arg192 (separation >6 Å). The altered binding conformation also removes 
the interaction of the chlorine with Gly45, leaving only the contact with Leu115. The other 
chlorine still contacts Leu158, Phe173 and Val243 but does not contact Met177, rather, it 
interacts with Val155. 
The extensive hydrophobic contacts made by both chlorines of 32, explains their importance 
in the binding of the fragment. In view of the proposed importance for the 4-hydroxy group 
of 32 in the inhibition of HsaD, it was unexpected to find the hydroxyl group makes no 
interactions with either the side chain or backbone of HsaD.  
The binding of 32 (Figure 3D), like the other acidic inhibitor investigated (27 Figure 3C) 
shows a distinct binding orientation from the uncharged sulphonamide (fragment 2) Figure 4. 
From these comparisons of binding sites, using fragment 2 as a starting point (Figure 4) there 
are two possible areas of expansion, the first is into the polar pocket that is accessed by the 
acidic groups of 27 and 32 (Figure 4C). The second area of expansion would be into the 
strongly negatively pocket in close proximity to the sulphonamide group of 2. Expansion into 
this polar pocket would mimic that of HOPDA (Figure 4D) which extends deep into the 
pocket and makes shorter range salt bridge with Arg192 (3.1 Å). 
 
Effects of inhibitors on growth of M. bovis BCG and M. tuberculosis H37Rv. 
In order to evaluate the specific anti-mycobacterial activity of the compounds, we tested them 
for inhibition of growth against E. coli. There was no inhibition observed at up to 100 µg/mL 
(Supplementary Figure 2). We also tested for any cytotoxic effect against RAW264.7 murine 
macrophage cells and again found no evidence of eukaryotic cell toxicity at concentrations up 
to 100 µg/mL (data not shown).  
None of the HsaD inhibitors had any effect on the growth of M. bovis BCG or M. 
tuberculosis when cultured in enriched MB7H9 broth. This observation is consistent with the 
effect seen in the gene deleted mutant strains. In order to test the proof of principle that 
inhibitors of HsaD would have an effect on the growth of M bovis BCG and M. tuberculosis 
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on cholesterol, we tested the fragments at concentrations ranging from 12.5 µg/mL to 200 
µg/mL in minimal growth media supplemented with cholesterol, using the SPOTi assay. 
Fragment 6 which is one of the most potent inhibitors of HsaD was also the most effective at 
inhibiting growth of both M. bovis BCG and M. tuberculosis treatment in the presence of 
cholesterol, with growth only at 12.5 µg/mL. On the other hand, fragment 8 which showed no 
inhibition of HsaD was also ineffective at concentrations up to 200 µg/mL in inhibiting the 
growth of either M. bovis BCG or M. tuberculosis on cholesterol.  
Fragment 2 was capable of inhibiting the growth of M. bovis BCG cells with an MIC of 
<12.5 µg/mL whilst fragment 24, inhibit the growth at 25 µg/ml. Fragment 27 on the other 
hand, did not appear to have an effect, with growth evident even at the highest concentration 
(200 µg/mL). As with fragment 2, both fragments 6 and 32, completely halted growth, with 
an MIC below 12.5 µg/mL. Isoniazid, gave an MIC of 0.1 mg/mL on bacteria grown on 
cholesterol.  
Similarly, the effect on M. tuberculosis growth following treatment with the fragments was 
also investigated during growth on cholesterol. Treatment with fragments 2 and 6 gave an 
MIC of 50 µg/mL and 25 µg/mL respectively, whilst fragments 24 and 32, 200µg/mL. No 
inhibition was observed with fragments 27 and 8 (growth present at 200 µg/mL) therefore, 
the MIC could not be calculated. Isoniazid was again found to have an MIC of 0.1 mg/mL.  
Fragment 27 is negatively charged and its ineffectiveness in the whole-cell inhibition may 
possibly be due to a lack of permeation through the lipid-rich mycobacterial cell-wall.  
Conclusions 
There is growing evidence of the importance of cholesterol for intracellular survival of M. 
tuberculosis and recurring evidence for the importance of the operon encoding HsaD as being 
essential for intracellular survival of M. tuberculosis. We present here evidence based on 
screening HsaD directly in a fragment based approach, that compounds identified as 
inhibitors of HsaD also have an effect on growth of M. tuberculosis and M. bovis BCG on 
cholesterol. HsaD is being identified as a target through virtual screening and whole cell 
assays linked with transcriptomic studies are also highlighting the importance of members of 
this operon. These studies provide a blueprint for extending the search and expanding the 
inhibitory moieties identified here in the continuing search for a new generation of anti-
tubercular agents.  
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Figure Legends 
Figure 1. Effect of deletion of hsaD gene on M. bovis BCG.    
Growth rates of ∆hsaD and wildtype M. bovis BCG in  MB7H9   (A)  on minimal medium 
containing 0.05% (v/v) tyloxapol, 0.05% (v/v) ethanol with no additional carbon source (B) 
or supplemented with, 100 µg/mL cholesterol (C) or 100 µg/mL glycerol (D). The 
intracellular survival of ∆hsaD M. bovis BCG relative to the wild-type in RAW264.7 cells 
(E) was determined as described in Methods. The mean ± standard deviation of three values 
is shown.  
Figure 2 Identification of fragment inhibitors of HsaD  
(A) NMR screening of DSF hits. Water-suppressed 1D 1H and STN NMR screening spectra 
for a representative fragment hit (fragment 2, at 1.2 mM) in the presence and absence of 
HsaD (10 µM) plus PMSF (100 µM). Only the fragment resonances in the aromatic region of 
the spectra are shown. The strong positive fragment signals in the presence of HsaD (purple 
spectrum) indicate binding, and this interaction is reduced by the addition of PMSF. (B) 
Inhibition of HsaD by DSF hits confirmed by NMR. Fragments identified by DSF as binding 
to HsaD were assayed for inhibition as described in materials and methods at 1 mM (filled 
bars). The mean of triplicate ± standard deviation is shown. Fragments are numbered as 
shown in Table 1. 100% activity was defined as the rate of enzymatic HOPDA hydrolysis by 
16 µg/mL HsaD with vehicle (no compound), which was 0.08 µmol/min/(mg protein). 
 
Figure 3.  Binding of inhibitors to HsaD.  
(A) The active site residues of apo HsaD (Lack et al., 2008) are overlaid onto the active site 
residues of HsaD bound to fragment 27 (fragment not shown). (B) Fragment 2, (C) Fragment 
27 and (D) Fragment 32 each bound to HsaD. In (A) HsaD structure with compound 2 has 
blue carbon atoms, apo-HsaD has gold carbon atoms. In (B) - (D) Green mesh is unbiased 
positive difference density contoured at 3σ. In (B) - (D) the protein is shown with blue carbon 
atoms, 2 is shown with grey carbon atoms, 27 with brown carbon atoms and 32 with cyan 
carbon atoms. Chlorines are coloured pink and hydrogen bonds are black dashed lines. 
Interacting residues are labelled. All figures were generated in CCP4MG (McNicholas et al., 
2011). 
 
Figure 4.  Comparison of the orientation of binding of fragments to the HsaD active site. 
(A) Shows the overlaid binding orientations of compounds 27 and 32. (B) shows the overlaid 
binding orientations of compounds 2 and 27. (C) shows the electrostatic potential surface 
map of HsaD in the pocket around compound 2. (D) shows an overlay of the structure of 
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HsaD bound to 2 with the structure of HsaD bound to HOPDA (PDB code 2wug) (Lack et 
al., 2010). Colour coding of carbon atoms is as per figure 3. HOPDA is shown with purple 
carbon atoms. CCP4MG was used to perform secondary structure alignments for as well as 
generating the electrostatic potential maps for (C) and (D).  
 
 
Supplementary Figure legends 
Supplementary figure 1:  
Cultures of Mycobacterium smegmatis grown on minimal medium containing cholesterol as 
carbon source are coloured when HsaD is deleted. Wildtype (WT) – on the left  and ΔHsaD on the 
right   Mycobacterium smegmatis were grown in 7H9 (containing 50μg/ml hygromycin for knockout) to an 
OD=1, washed twice with sterile PBS and then used to inoculate (1/100 dilution) a200mL culture of minimal 
medium containing 0.05% (v/v) ethanol, 0.05% (v/v) tyloxapol and 50μg/ml cholesterol and grown at 37˚C for 
36 hours.  
 
Supplementary figure 2. 
 
Effect of fragments on the growth of E. coli JM109 in LB medium  
(A) fragment 2; (B) fragment 24; (C) fragment 27; (D) fragment 32; and (E) fragment 6. Liquid 
cultures in LB were diluted to an OD 600 of 0.1 and fragments were added Briefly, an overnight 
culture was sub-cultured and was diluted to an OD600 of 0.1 in LB containing 12.5 µg/mL, 25 µg/mL, 
50µg/mL, or 100 µg/mL of fragments. Absorbance readings at 600nm represent means of triplicates 
± S.D.  
 
Page 30 of 42
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
  
 
 
Figure 1. Effect of deletion of hsaD gene on M. bovis BCG.   Growth rates of ∆hsaD and wildtype M. bovis 
BCG in  MB7H9   (A)  on minimal medium containing 0.05% (v/v) tyloxapol, 0.05% (v/v) ethanol with no 
additional carbon source (B) or supplemented with , 100 µg/mL cholesterol (C) or 100 µg/mL glycerol (D). 
The intracellular survival of ∆hsaD M. bovis BCG relative to the wild-type in RAW264.7 cells (E) was 
determined as described in Methods. The mean ± standard deviation of three values is shown.  
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Figure 3.  Binding of inhibitors to HsaD. (A) The active site residues of apo HsaD (Lack et al., 2008) are 
overlaid onto the active site residues of HsaD bound to fragment 27(fragment not shown). (B) Fragment 2 , 
(C) Fragment 27  and  (D) Fragment 32  each bound to HsaD. In (A) HsaD structure with compound 2 has 
blue carbon atoms, apo-HsaD has gold carbon atoms. In (B) - (D) Green mesh is unbiased positive 
difference density contoured at 3σ. In (B) - (D) the protein is shown with blue carbon atoms, 2 is shown 
with grey carbon atoms, 27 with brown carbon atoms and 32 with cyan carbon atoms. Chlorines are 
coloured pink and hydrogen bonds are black dashed lines. Interacting residues are labelled. All figures were 
generated in CCP4MG (McNicholas et al., 2011).  
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Figure 4.  Comparison of the orientation of binding of fragments to the HsaD active site.  
(A) Shows the overlaid binding orientations of compounds 27 and 32. (B) shows the overlaid binding 
orientations of compounds 2 and 27. (C) shows the electrostatic potential surface map of HsaD in the pocket 
around compound 2. (D) shows an overlay of the structure of HsaD bound to 2 with the structure of HsaD 
bound to HOPDA (PDB code 2wug) (Lack et al., 2010). Colour coding of carbon atoms is as per figure 3. 
HOPDA is shown with purple carbon atoms. CCP4MG was used to perform secondary structure alignments 
for as well as generating the electrostatic potential maps for (C) and (D).  
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Table 1 
Compound TM 
shifts* 
NMR PMSF displacement Structure 
 1 1.78; 
2.64; 
2.64 
Hit Displaced 
 
2 0.77; 
0.38; 
0.38 
Hit Displaced 
 
3 0.55; 
0.76; 
0.76 
Hit Displaced 
 
4 0.55;  
-2.26;  
-2.26 
Hit Displaced 
 
5 0.92; 
1.13; 
1.13 
Hit Not displaced  
(PMSF bound) 
 
6 0.70; 
1.13; 
1.13 
Hit Not displaced  
(PMSF not bound) 
 
7 0.82; 
0.38; 
0.76 
Hit Displaced 
 
N
N
N
N
O
S ONH2
O
Cl Cl
S O
O
NH2
CH3
S O
OH
Cl
N
H
N
NCl
OO
Cl Cl
OH
CH3
S
O
N
O NH2
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Table 1. Fragments from a 1258 member library producing a significant shift in HsaD TM. and 
where saturation NMR demonstrated displacement of the ligand by PMSF. 
The compounds are numbered sequentially :  4-((1H-benzo[d][1,2,3] triazol-1-yl)methyl)morpholine 
compound 1; 3,5,-dichloro-benzenesulfonamide   compound 2; methyl 4-aminothiophene-3-
carboxylate compound 3; 3-chlorothiophene-2-carboxylic acid , compound 4; 7-chloro-4-(piperazin-
1-yl)quinolone, compound 5; ethyl 3,5-dichloro-4-hydroxybenzoate, compound 6; 4-(piperidin-1-
ylsulfonyl)aniline, compound 7. 
*The TM shifts are shown for each compound tested with a positive result for DSF, performed as 
described in materials and methods  at 2.5 mM final fragment concentration per well. Structures are 
drawn with ChemDraw Ultra 12.0 (CambridgeSoft). Hits from the primary DSF screen were re-tested 
twice to confirm results of the initial screen and finally validated for protein binding using NMR 
spectroscopy (as shown in Fig. 2A) (after Ciulli & Abell, 2007; Mayer & Meyer, 1999). 
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ID Compound Structure 
IC50  
(mM) 
MIC (µg/mL) 
Growth on cholesterol 
M. bovis BCG M. tuberculosis 
2 
3,5,-dichloro-
benzenesulfonamide 
 
 
0.43 
±0.03 
<12.5 25 
8 
Benzenesulfonamide 
 
 
NI NI NI 
24 
3,5-dichlorosulfanilamide 
 
 
 
0.18±0.0
1 
25 200 
27 
3,5-dichloro-4-
hydroxybenzenesulphonic acid 
 
 
0.27 
±0.03 
>200 >200 
6 
ethyl 3,5-dichloro-4-
hydroxybenzoate 
 
 
0.55±0.0
7 
<12.5 <12.5 
S ONH2
O
Cl Cl
S ONH2
O
S ONH2
O
Cl Cl
NH2
OO
Cl Cl
OH
CH3
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Table 2 Effects of (A)Fragment 2 and its derivatives  and  (B) fragment 6 and a derivative on HsaD enzymic activity and growth of mycobacteria 
on cholesterol as carbon source.  
NI indicates no inhibition observed at 5mM for inhibition of enzyme activity and no inhibition of growth at 200 µg/mL as described in Methods. 
See supplementary table 1 for full list. 
 
 
 
 
32 
3,5-dichloro-4-hydroxybenzoic 
acid 
 
 
0.54 
±0.01 
<12.5 200 
OOH
ClCl
OH
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Table 3 Processing and refinement statistics for X-ray crystallographic structures. 
Structure HsaD - 2 HsaD - 27 HsaD - 32 
PDB Code 5JZB 5JZ9 5JZS 
Space Group I 212121 I 212121 I 212121 
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 
a, b, c (Å) 82.03, 82.23, 194.25 81.73, 82.32, 193.58 81.92, 82.27, 195.13 
Processing Statistics 
Resolution Range (Å) 50.9-2.1 75.75-2.68 97.57-2.27 
Unique reflections a 38,700 18,699 (2,445) 30,015 (2,024) 
Rmerge 0.134 (0.469) 0.231 (0.895) 0.109 (0.453) 
<I/σ(I)>a 8 (2.6) 4.4 (1.5) 7.7 (1.4) 
Completeness % a 100 (100) 99.6 (99.0) 99.3 (57.4) 
Multiplicity a 6.3 (5.3) 4.4 (4.5) 4.9 (3.1) 
Refinement Statistics 
Rwork % 23.51 24.05 23.48 
Rfree
 %  20.55 21.27 20.25 
RMS bond angle (°) 1.28 0.89 1.20 
RMS bond length (Å) 0.005 0.004 0.009 
Ramachandran Statistics
b
 
Preferred region % 97.5 98.2 98.6 
Allowed region % 2.3 1.8 1.4 
Outliers % 0.2 0 0 
a
 Numbers in parentheses are for the highest resolution shell. 
b 
Ramachandran statistics were calculated using MolProbity.
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Supplementary Figure 1: Cultures of Mycobacterium smegmatis grown on minimal medium 
containing cholesterol as carbon source are coloured when HsaD is deleted. Wildtype (WT) – on 
the left and ΔHsaD on the right   Mycobacterium smegmatis were grown in 7H9 (containing 50μg/ml 
hygromycin for knockout) to an OD=1, washed twice with sterile PBS and then used to inoculate (1/100 
dilution) a200mL culture of minimal medium containing 0.05% (v:v) EtOH, 0.05% (v:v) tyloxapol and 50μg/ml 
cholesterol and grown at 37˚C for 36 hours.  
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Supplementary figure 2: Effect of fragments on the growth of E. coli JM109 in LB medium  
(A) fragment 2; (B) fragment 24; (C) fragment 27; (D) fragment 32; and (E) fragment 6. Liquid 
cultures in LB were diluted to an OD 600 of 0.1 and fragments were added Briefly, an overnight 
culture was sub-cultured and was diluted to an OD600 of 0.1 in LB containing 12.5 µg/mL, 25 µg/mL, 
50µg/mL, or 100 µg/mL of fragments. Absorbance readings at 600nm represent means of triplicates 
± S.D.  
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Fragment  Fragment name IC50 /mM 
1 
4-((1H-benzo[d][1,2,3] triazol-1-yl)methyl) 
morpholine ND 
2 3,5,-dichloro-benzenesulfonamide 0.43 ±0.03 
3 methyl 4-aminothiophene-3-carboxylate * 
4 3-chlorothiophene-2-carboxylic acid  * 
5 7-chloro-4-(piperazin-1-yl)quinolone * 
6 ethyl 3,5-dichloro-4-hydroxybenzoate 0.55±0.07 
7 4-(piperidin-1-ylsulfonyl)aniline * 
8 Benzenesulfonamide no inhibition 
9 3-chlorobenzenesulfonamide 5.14 ±0.6 
10 3,5-difluorobenzenesulfonamide no inhibition 
11 2,5-dichlorobenzenesulfonamide 1.96 ±0.12 
12 
3,5-bis(trifluor methyl) 
benzenesulphonamide ND 
13 4-chlorobenzenesulfonamide no inhibition 
14 3-bromobenzenesulfonamide 2.74 ±0.31 
15 4-sulfamoylbenzoic acid no inhibition 
16 3-nitrobenzenesulfonamide * 
17 4-nitrobenzenesulfonamide no inhibition 
18 3-aminobenzenesulfonamide no inhibition 
19 p-aminobenzenesulfonamide No inhibition 
20 3-methoxybenzenesulfonamide * 
21 4-methoxybenzenesulfonamide * 
22 4-hydroxybenzenesulfonamide no inhibition 
23 p-toluenesulfonamide no inhibition 
24 3,5-dichlorosulfanilamide 0.18 ±0.01 
25 2,5-dichloro-N,N-dimethylsulanilamide 3.63 ±0.24 
26 3,5-dibromosulfanilamide 2.16 ±0.15 
27 3,5-dichloro-4-hydroxybenzenesulphonate 0.27 ±0.03 
28 3,5-dichlorobenzoate no inhibition 
29 3-chloro-4-hydroxybenzoate no inhibition 
30 p-hydroxy benzoate no inhibition 
31 methyl 3,5-dichloro-4-hydroxybenzoate  0.73 ±0.03 
32 3,5-dichloro-4-hydroxybenzoate 0.54 ±0.01 
33 4-amino-3,5-dichlorobenzoate 0.54 ±0.02 
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Table 1 Supplementary Inhibition of HsaD enzymic activity by a sublibrary of compounds based on 
fragments 2 and 6 from the initial screen  (Table 1). 
The values for IC50 were determined from the inhibition of HsaD enzymic activity by the fragments 
as indicated in Materials and Methods. The values shown are averages +/- standard deviation of 
three independent determinations.  No inhibition indicates that the compounds were not inhibitiory 
at 5mM or at the highest soluble concentration which could be obtained. The * indicates that 
inhibition was observed but that it did not reach 50% at either b5mM or the highest soluble 
concentration which could be obtained. 
34 3,5-dichlorobenzamide * 
35 1,3-dichloro-6-nitrobenzene 2.14 ±0.21 
36 4-amino benzoic acid * 
37 m-aminobenzoic acid no inhibition 
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